Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CARTHAGO

Financiado

Cartilaginous tissue regeneration by non viral gene therapy taking the hurdles...

Cartilaginous tissue regeneration by non viral gene therapy taking the hurdles towards efficient delivery Chronic low back pain due to intervertebral disc (IVD) degeneration and osteoarthritis (OA) worldwide impact human health and well-being due to pain and impaired mobility. Non-viral gene therapy has great promise as safe and preci... ver más

31/08/2024

UMC UTRECHT

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

UNIVERSITAIR MEDISCH CENTRUM UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-08-31

MSCA-ITN-2020: Innovative Training Networks

I+D

Cerrada hace 5 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

UMC UTRECHT

265.62K€ | Lider

NOVEDADES AGRICOLAS

480.00K€ | Participante

INEB

237.72K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TargetCaRe Targeting Cartilage Regeneration in joint and intervertebral... 4M€ Cerrado

PGC2018-102047-B-I00 ANDAMIOS BIOHIBRIDOS ASOCIADOS CON APATITOS NANOCRISTALINOS... 133K€ Cerrado

PCIN-2015-113 NANOESTRUCTURAS DISEÑADAS PARA TERAPIAS CELULARES AVANZADAS 150K€ Cerrado

PCIN-2015-261 NANOCOMPOSITES JERARQUICOS DOPADOS IONICAMENTE COMO SOPORTES... 110K€ Cerrado

EnBioN Engineering the Biointerface of Nanowires to Direct Stem Cel... 1M€ Cerrado

NANEMIAR Nanomedicine Approach to Normalize Erythrocyte Maturation in... 3M€ Cerrado

Duración del proyecto: 47 meses Fecha Inicio: 2020-09-02
Fecha Fin: 2024-08-31

Líder del proyecto

UNIVERSITAIR MEDISCH CENTRUM UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Chronic low back pain due to intervertebral disc (IVD) degeneration and osteoarthritis (OA) worldwide impact human health and well-being due to pain and impaired mobility. Non-viral gene therapy has great promise as safe and precision treatment to restore IVD and joint tissue health. However, the lack of accessibility of the affected cartilaginous tissues to drugs has inhibited progress in this field. We will finally fulfil the promise of non-viral gene therapy in these diseases. We will do this through educating 15 young researchers in 10 different countries in physics, quality by design (QbD), nucleic acid chemistry, nanomedicine, cartilage and IVD biology, ethics, entrepreneurship and academic transferable skills. This highly multidisciplinary team will exploit the potential of gene therapy in IVD and joint disease by taking a multi-faceted approach towards the delivery and activity of oligonucleotides and encoding nucleic acids (NA). Cell and tissue delivery will be achieved by nucleic acid modification, innovative nanocarriers and tissue targeting, supported by QbD. Ultrasound will for the first time be used to enhance NA tissue penetration and transfection, and to trigger local release from systemically administered endogenous albumin-NA conjugates. Imaging tools will be developed to monitor in vivo regeneration, saving numerous animal lives in the future. Moreover, we will set up an educational framework for embedding biomedical ethics in biomedical research and valorisation, providing a firm and sustainable basis for Responsible Research and Innovation for future biomedical science and technology. Participation of a patient organisation and a scientific organisation experienced in the dialogue with society, will ensure researchers at ease in communicating with different audiences. Hence CARTHAGO will deliver the agile scientists freely moving between sectors and firmly anchored in society, required to take science and innovation to the next level in Europe.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores